KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Change in Receivables: 2009-2025

Historic Change in Receivables for Neogenomics (NEO) over the last 17 years, with Sep 2025 value amounting to $2.4 million.

  • Neogenomics' Change in Receivables fell 51.16% to $2.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 million, marking a year-over-year decrease of 94.24%. This contributed to the annual value of $19.3 million for FY2024, which is 67.71% up from last year.
  • According to the latest figures from Q3 2025, Neogenomics' Change in Receivables is $2.4 million, which was up 322.35% from -$1.1 million recorded in Q2 2025.
  • In the past 5 years, Neogenomics' Change in Receivables ranged from a high of $9.1 million in Q1 2024 and a low of -$3.9 million during Q1 2021.
  • For the 3-year period, Neogenomics' Change in Receivables averaged around $3.0 million, with its median value being $2.4 million (2025).
  • In the last 5 years, Neogenomics' Change in Receivables slumped by 168.52% in 2021 and then skyrocketed by 1,271.46% in 2023.
  • Quarterly analysis of 5 years shows Neogenomics' Change in Receivables stood at $7.2 million in 2021, then rose by 7.69% to $7.7 million in 2022, then crashed by 118.30% to -$1.4 million in 2023, then surged by 37.11% to -$888,000 in 2024, then crashed by 51.16% to $2.4 million in 2025.
  • Its Change in Receivables stands at $2.4 million for Q3 2025, versus -$1.1 million for Q2 2025 and $668,000 for Q1 2025.